This subgroup, presented in collaboration with the Society for Immunotherapy of Cancer, will address how the integration and translation of cell biology is necessary for effective cancer immunotherapy applications. The speakers will provide an overview of the critical cellular mediators and processes in cancer cell biology as it relates to success of immunotherapy, highlighting recent advances in immune escape/resistance, mutational landscape/neoantigen discovery, and current immunotherapeutic applications.
Organizers:
Daniel J. Powell, Jr., PhD – University of Pennsylvania
Keith L. Knutson, PhD – Mayo Clinic Jacksonville
Schedule:
Theme 1: Tumor Plasticity and Mechanisms of Immune Resistance
1:30-1:55 pm: Mechanisms of Resistance to Cytotoxic Cell Killing
Steven M. Frisch, PhD – West Virginia University
1:55-2:25 pm: Cytokines and Tumor Immune Resistance
Claudia Palena, PhD – National Cancer Institute
Theme 2: Modifying Malignant Cells to Enhance Susceptibility to Immunotherapy
2:25-2:55 pm: Radiation Therapy and the Immune Response
Andy J. Minn, MD, PhD – University of Pennsylvania
2:55-3:20 pm: Epigenetic Potentiation of Immunotherapies
Kunle Odunsi, MD, PhD – Roswell Park Cancer Institute
3:20-3:35 pm: Break
Theme 3: Neoantigen Discovery and Applications
3:35-4:00 pm: Bioinformatic Pipelines
Yan Asmann, PhD – Mayo Clinic Jacksonville
4:00-4:30 pm: Mutation Load, Outcomes in Cancer and Personalized Cancer Vaccines
Aaron Miller, MD, PhD – University of California San Diego Health
Theme 4: Clinical Translation and Current Use of Immunotherapies
4:30-5:00 pm: Immune Checkpoint Blockade
Keith L. Knutson, PhD – Mayo Clinic Jacksonville
5:00-5:30 pm: Adoptive T Cell Therapy
Bruce Levine, PhD – University of Pennsylvania
To register, or find more information, please click HERE.
Please note: This session is taking place during the ASCB/EMBO 2017 Meeting from December 2-6, 2017.